Market Cap 48.28M
Revenue (ttm) 0.00
Net Income (ttm) -80.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,056,941
Avg Vol 1,802,052
Day's Range N/A - N/A
Shares Out 31.56M
Stochastic %K 16%
Beta 1.74
Analysts Strong Sell
Price Target $11.50

Company Profile

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 207 8979
Website: acrivon.com
Address:
480 Arsenal Way, Suite 100, Watertown, United States
Dani_G_German
Dani_G_German Feb. 24 at 2:02 PM
$ACRV I’m glad they’re out spreading the news
0 · Reply
Dou_said_it
Dou_said_it Feb. 24 at 1:20 PM
$ACRV Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
0 · Reply
Funktrade
Funktrade Feb. 23 at 7:25 PM
$ACRV THIS IS FUCKING PATHETIC 😡😡😡😡😡😡😡😡😡😡😡😡😡
0 · Reply
vcn_PL
vcn_PL Feb. 23 at 3:49 PM
$ACRV Guys… $1.5 is honestly laughably low at this point. January numbers were solid, insider buying keeps coming in, last-minute ESGO oral-presentaton, they dropped the news about getting their own lab up and running. Trading below cash in the bank + main endometrial cancer competitor basically imploding? Fast Track for ACR-368 unlocked. This does NOT scream “more dead money” to me. 😄
1 · Reply
Dou_said_it
Dou_said_it Feb. 23 at 1:28 PM
$ACRV Something big is coming… « Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress »
0 · Reply
KingShark7
KingShark7 Feb. 23 at 12:07 PM
$ACRV still needs some time
0 · Reply
Monty3030
Monty3030 Feb. 20 at 3:37 PM
$ACRV Everyone needs to be patient and let the market do its thing.
0 · Reply
Funktrade
Funktrade Feb. 20 at 3:29 PM
$ACRV this is BULLSHIT . 😡😡😡😡😡
0 · Reply
nmarrone2207
nmarrone2207 Feb. 20 at 3:23 PM
$ACRV starting to feel like shorts are going to be able to drive this lower.... usually when cant undertsand why its being shorted, they know something we do
1 · Reply
PreGigs
PreGigs Feb. 20 at 2:39 PM
$ACRV scooping up more :)
0 · Reply
Latest News on ACRV
What To Buy After You Sell The Russell 2000

Apr 3, 2024, 3:07 AM EDT - 2 years ago

What To Buy After You Sell The Russell 2000

AVUV IJR IWM IWN MLYS NXT SKWD


Acrivon: Precision-Testing Your Trial Patients Before Enrolment

Mar 26, 2023, 9:53 AM EDT - 3 years ago

Acrivon: Precision-Testing Your Trial Patients Before Enrolment


Dani_G_German
Dani_G_German Feb. 24 at 2:02 PM
$ACRV I’m glad they’re out spreading the news
0 · Reply
Dou_said_it
Dou_said_it Feb. 24 at 1:20 PM
$ACRV Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
0 · Reply
Funktrade
Funktrade Feb. 23 at 7:25 PM
$ACRV THIS IS FUCKING PATHETIC 😡😡😡😡😡😡😡😡😡😡😡😡😡
0 · Reply
vcn_PL
vcn_PL Feb. 23 at 3:49 PM
$ACRV Guys… $1.5 is honestly laughably low at this point. January numbers were solid, insider buying keeps coming in, last-minute ESGO oral-presentaton, they dropped the news about getting their own lab up and running. Trading below cash in the bank + main endometrial cancer competitor basically imploding? Fast Track for ACR-368 unlocked. This does NOT scream “more dead money” to me. 😄
1 · Reply
Dou_said_it
Dou_said_it Feb. 23 at 1:28 PM
$ACRV Something big is coming… « Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress »
0 · Reply
KingShark7
KingShark7 Feb. 23 at 12:07 PM
$ACRV still needs some time
0 · Reply
Monty3030
Monty3030 Feb. 20 at 3:37 PM
$ACRV Everyone needs to be patient and let the market do its thing.
0 · Reply
Funktrade
Funktrade Feb. 20 at 3:29 PM
$ACRV this is BULLSHIT . 😡😡😡😡😡
0 · Reply
nmarrone2207
nmarrone2207 Feb. 20 at 3:23 PM
$ACRV starting to feel like shorts are going to be able to drive this lower.... usually when cant undertsand why its being shorted, they know something we do
1 · Reply
PreGigs
PreGigs Feb. 20 at 2:39 PM
$ACRV scooping up more :)
0 · Reply
Investman10
Investman10 Feb. 20 at 12:13 AM
$ACRV 🤞🏻
0 · Reply
Kinderla
Kinderla Feb. 19 at 5:58 PM
$ACRV $IBG is a small Australia-based beverage company (founded 2019, public Sep 2024) trading near $4.50 with a ~$3.2M MC and over $2M annual revenue. The company plans to merge with BlockFuel Energy, a private Texas oil & gas firm focused on converting stranded natural gas into power for BTC miners and data centers. Under the Feb 11 update (feeds.issuerdirect.com/news), $IBG holders would own ~10% of the combined company, with BlockFuel valuations estimated around $200M$350M. The merger makes strategic sense: BlockFuel gains a reverse IPO/Nasdaq listing, while $IBG gains capital and a new direction. The key link is CEO Dan Lanskey, who leads BlockFuel and sits on IBG’s board, with prior Oklahoma oil & gas startup experience. If completed, $IBG shareholders retain ~10% exposure to a potential energy/AI infrastructure play. This gives $IBG 2x potential in the short term and 5x or more possibility when the merger completes.
1 · Reply
Kinderla
Kinderla Feb. 19 at 4:10 PM
$ACRV Big potential, low float merger play: $IBG https://feeds.issuerdirect.com/news-release.html?newsid=7782997587767899&symbol=IBG
0 · Reply
Dani_G_German
Dani_G_German Feb. 19 at 12:16 AM
0 · Reply
Dylberts
Dylberts Feb. 18 at 3:30 PM
$ACRV had some good news today, borrowed and short rates are very low, and now all we had to do is wait and see— Not expecting much off this news, but it is a good step forward overall
1 · Reply
Trinity031983
Trinity031983 Feb. 18 at 3:27 PM
0 · Reply
BioTuesdays
BioTuesdays Feb. 18 at 3:04 PM
$ACRV has announced the completion and certification of its internal, wholly-owned and operated Clinical Laboratory Improvement Amendment (CLIA)-certified laboratory, located on premises in Watertown, Massachusetts. https://biotuesdays.com/2026/02/18/acrivon-launches-internal-clia-certified-lab/
0 · Reply
Geraldgenofranco1953
Geraldgenofranco1953 Feb. 18 at 1:25 PM
$SLS $IBRX $ALT $CABA $ACRV Let us sail in this sea Captain Sparo! I am in all your groups!
0 · Reply
jacksparo
jacksparo Feb. 18 at 1:23 PM
$SLS $IBRX $ALT $CABA $ACRV Another important day for some BIOTECH stocks! I have all my scanners, plus my plans and what I need to watch and do! I am sharing my live updates and trading plans in my Telegram BIOTECH stocks live group! Let us see what today will bring!
1 · Reply
Dou_said_it
Dou_said_it Feb. 18 at 12:41 PM
$ACRV news in One week… this still red. Hope we see a pump the 27 February.
0 · Reply
Dou_said_it
Dou_said_it Feb. 18 at 9:43 AM
$ACRV well…
0 · Reply
thefly2
thefly2 Feb. 17 at 4:08 PM
$HOTH $ACRV both holding up well
0 · Reply